VirusInhibitex: Phase II Clinical Trial for ShinglesWikinvest--Inhibitex, Inc. INHX
Check out Wikinvest
Inhibitex, Inc. (NASDAQ: INHX) increased 10% on Friday after announcing completed enrollment in their Phase II clinical trial of FV-100 for shingles. With top-line data expected later this quarter, expect buying pressure to increase in the short term.
If you would like more Subscribe To BioPharma Investor for everyday stock news and up to date FDA decisions. Biopharma Investor
